Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fractyl Health (GUTS) Cash from Financing Activities (2023 - 2025)

Fractyl Health (GUTS) has disclosed Cash from Financing Activities for 3 consecutive years, with $78.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Financing Activities rose 48102.47% year-over-year to $78.1 million, compared with a TTM value of $79.8 million through Sep 2025, down 20.67%, and an annual FY2024 reading of $101.2 million, up 268.94% over the prior year.
  • Cash from Financing Activities was $78.1 million for Q3 2025 at Fractyl Health, up from $1.5 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $101.0 million in Q1 2024 and bottomed at -$556000.0 in Q4 2023.
  • Average Cash from Financing Activities over 3 years is $18.9 million, with a median of $162000.0 recorded in 2024.
  • Peak annual rise in Cash from Financing Activities hit 5050200.0% in 2024, while the deepest fall reached 117.86% in 2024.
  • Year by year, Cash from Financing Activities stood at -$556000.0 in 2023, then soared by 112.05% to $67000.0 in 2024, then skyrocketed by 116449.25% to $78.1 million in 2025.
  • Business Quant data shows Cash from Financing Activities for GUTS at $78.1 million in Q3 2025, $1.5 million in Q2 2025, and $171000.0 in Q1 2025.